TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from baseline the rate of production of IDL Apo B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline the rate of production of LDL Apo B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline the rate of production of HDL Apo A1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline the Fractional Catabolic Rate of VLDL1 Apo B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of hVISA and other resistant staphylococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Functional outcome 90 days after stroke onset
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in sitting systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cough specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite renal outcome (Estimated Glomerular Filtration Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Children's Psychiatric Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: changes in pp65 and/or IE-1 specific CMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of hospitalisation (days)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Electrodermal skin conductance activity (EDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of Thalidomide
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of FMT in treating SR-GI-aGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in faecal incontinence scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 3-Month Progression-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: adipose and skeletal muscle characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ectopic fat accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Position sense (Proprioception) of the knee joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement sense (Proprioception) of the knee joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change in Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Distress Thermometer Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of Blood Concentration-time of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Lowering Response to Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving LDL-C and non-HDL-C treatment goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Trans-renal difference/ratio of plasma concentrations of coagulation measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acute cell mediated graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Migration of the acetabular component
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Without Wound Healing Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Patients Without Major Adverse Events Within 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Device Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With a Grade 3 and 4 Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Achieve a Confirmed Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (Utility) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Spatial Orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Positive & Negative Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Management of cachexia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of consent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cognitive decline as measured by memory tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum Inspired Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hyperemesis Gravidarum severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cerebral Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate clearance kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse Rate accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Oxygen accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiration rate accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Temperature accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mycological investigation results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes from baseline associated with severe CAV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of cases with gold standard diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients with changed respiratory diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Mean Diabetic Neuropathy Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Responders at the 30% Improvement Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brazelton's neonatal behavior assessment scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity defined as any grade 3 or greater organ toxicity, or any grade 4 or greater hematological toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Passive plantarflexion and dorsiflexion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of Estrogen Receptor (ER-beta)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progesterone Receptor (PR) Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human Epidermal Growth Factor Receptor 2 (Her2) Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Energy compensation including beverages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Energy compensation not including beverages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fistula healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time for fistula closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: freedom from all cause death
Endpoint domain: Mortality/survival
Primary endpoint: unplanned index limb amputation
Endpoint domain: Adverse events/effects
Primary endpoint: stent patency via Color Duplex Ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge Improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Tumour-specific death
Endpoint domain: Mortality/survival
Primary endpoint: overall safety of MPCs plus carrier
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Complete Sensory Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Complete Motor Blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Onset Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Global Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Adverse Events including SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Child Health Care Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity and specificity of MDCTCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in blood pressure control pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete remission rate (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Urinary and Fecal Excretion of LY2886721 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk Factors for severe infection
Endpoint domain: Adverse events/effects
Primary endpoint: Immunological mechanisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Long term outcome
Endpoint domain: Life impact
Primary endpoint: Median time of survival
Endpoint domain: Mortality/survival
Primary endpoint: Participants Meeting Predefined Safety Criteria for Vital Signs
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With Laboratory Abnormalities Meeting Predefined Criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With Clinically Significant Abnormalities Physical Examination
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of fasting
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sustained virological response (SVR) 12 weeks after end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful full block at T11-L1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Primary closure of macular hole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of cervical cancer
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change From Baseline in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Who Completed the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Regardless Whether They Completed the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Were Compliant to the 10 cm^2 Patch
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Subjects Who Develop Chronic Neuropathic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuropathic Pain Symptom Inventory (NPSI) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline of the Itch Severity Score (ISS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cmax of S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cmax of R-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC0-144 of S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Hounsfield units of coronary calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in serum TMAO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With at Least One Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Adverse Drug Reaction (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Preparedness for Caregiving Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Drinks Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative and in-hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Glenoid Version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glenoid Inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of laboratory values outside pre-determined ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Success Based on the Investigator's Global Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in symptoms of Autism spectrum disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal imaging time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in L/B ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum GFAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of women exclusively breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Running Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Facial bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Facial bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood ammonia level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Continuity in HIV care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Access to HCV care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Reversal Time of Rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxoplasma IgG titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBMC gene expression profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Program Adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: wound healing change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of microorganism isolated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Bacterial Vaginosis Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients in remission
Endpoint domain: Mortality/survival
Primary endpoint: Change in NCCN distress thermometer score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ADHD Rating Scale-IV-Parent version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive leg lift test (ELJP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of keratoconus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: blood oxytocin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resting EEG time-frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 6 Minute Walking Distances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active and passive range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cutaneous microvascular endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV vaccine series completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Variation of the angle of Vertebral Kyphosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Variation of the angle of lateral vertebral inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction of Port Wine Stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Complete Clearance of Actinic Keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pancreatic volume measured by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreatic volume measured by Ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plaque volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recommended dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body weight change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to additional therapy for RVO
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Primary correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Presence of anti-ficolin-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood level of S100B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Achieving Anti-Tetanus Toxoid (TTd) Antibody Concentrations >= 0.1 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Anti-Diphtheria Toxoid (DTd) Antibody Concentrations >= 0.1 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Increase in VTA Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer-free status confirmed by re-biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with high parathyroid hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in perceived barriers to adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and specificity of CESM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to peptide immunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-invasive blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cytokine secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline peak VO2 (ml/kg/min) at 12 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline MLHFQ at 12 week
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life